A phase 2 clinical study for patients with primary biliary cholangitis (PBC) in the U.S.
A phase 2 clinical study for patients with PBC outside of the U.S.
A phase 3 clinical study for patients with fibrosis due to nonalcoholic steatohepatitis (NASH)
You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.
You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.
The link you have selected will take you outside of Intercept Pharmaceuticals’ corporate website.
The site you will be entering is intended for U.S. audiences only.
If you are a healthcare provider looking for product information, visit ocalivahcp.com.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.
Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.
United States (US)
European Union (EU)
Canada
Israel
Switzerland
Australia
Liechtenstein
United Arab Emirates (UAE)
Exploring Racial Differences and Disparities in PBC Care